Investing, Biotechnology, Venture Capital, Science, Immune System.
counterparts, potentially improving their therapeutic efficacy and safety profiles. The strategies discussed, such as half-life extension, targeted delivery, and receptor biasing, offer promising avenues for further exploration and development. However, as illustrated by the case of IL-2